Holen Sie sich die Stockscreener-App
0.296
0.47%
-0.0014
Schlusskurs vom Vortag:
$0.2974
Offen:
$0.295
24-Stunden-Volumen:
649.61K
Relative Volume:
0.47
Marktkapitalisierung:
$10.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-47.73M
KGV:
-0.0206
EPS:
-14.3996
Netto-Cashflow:
$-13.18M
1W Leistung:
-7.53%
1M Leistung:
-19.78%
6M Leistung:
-36.15%
1J Leistung:
-79.59%
1-Tages-Spanne:
$0.2871
$0.3062
1-Wochen-Bereich:
$0.2871
$0.3346
52-Wochen-Spanne:
$0.261
$1.5257
Gt Biopharma Inc Stock (GTBP) Company Profile
Firmenname
Gt Biopharma Inc
Sektor
Branche
Telefon
(800) 304-9888
Adresse
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP vs MOBBW, PSNYW, GOODO, SHMD, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.86 | 2.83B | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.89 | 388.34M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.88 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.45 | 348.74M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
48.03 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Eingeleitet | ROTH MKM | Buy |
| 2021-05-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-13 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-17 | Eingeleitet | ROTH Capital | Buy |
Gt Biopharma Inc Aktie (GTBP) Neueste Nachrichten
GT Biopharma Shareholders Approve Reverse Split and Incentive Plan - TipRanks
GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes - Stock Titan
GT Biopharma Q2 Results: Net Loss Falls To $4.5 Million - scanx.trade
Gt Biopharma Reports Second Quarter 2026 Financial Results - TradingView
GTBP: Q2 2026 net loss narrowed to $4.5M as clinical programs advance and cash runway extends to Q4 2026 - TradingView
GT Biopharma Reports Second Quarter 2026 Financial Results - The Manila Times
GT Biopharma (GTBP) cuts net loss but flags going concern and Nasdaq risk - Stock Titan
GT Biopharma Inc (NASDAQ: GTBP) Share Price, GTBP Stock News, GTBP Share Price & Updates - kalkine.ca
GT Biopharma Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
GT Biopharma Inc (GTBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
GT Biopharma Inc (GTBP) Stock News Today - tradingkey.com
GT Biopharma’s TriKE® Program: Pipeline, Progress, & What’s Ahead - SmallCap Asia
GTBP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
GT Biopharma (GTBP) Slips 4.65% to $0.29, Testing Critical Support Near $0.28Trend Reversal Picks - dars.gov.et
GT BIOPHARMA INC (GTBP) Stock Chart - ChartMill
GT Biopharma Edges Higher as Biotech Sector Sees Renewed Interest — GTBP Hovers Near Key LevelsSmart Beta Flow - po-news-eg.net
GT Biopharma Inc (GTBP) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
GT Biopharma Inc (GTBP) Cash Flow - TradingKey
GT Biopharma Inc (GTBP) Income Statement - tradingkey.com
GTBP|GT Biopharma Inc|Price:0.335|Chg%:+0.011 - TradingKey
GT Biopharma Inc (GTBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GTBP|GT Biopharma Inc|Price:0.310|Chg%:-0.011 - TradingKey
GT Biopharma Inc (GTBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GT Biopharma Inc (GTBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GTBP|GT Biopharma Inc|Price:0.324|Chg%:-0.011 - TradingKey
GT Biopharma(GTBP) Stock Options Chain | Quotes & News - Moomoo
GT Biopharma, Inc. Revenue Breakdown – NASDAQ:GTBP - TradingView
GT Biopharma Inc (GTBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price to earnings forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
Price to earnings forward of GT Biopharma Inc – SWB:OXIA - TradingView
Immunotherapy Breakthroughs Propel Clinical Momentum Ahead of ESMO Congress - Baystreet.ca
GT Biopharma (GTBP) Slides to $0.42 Amid Continued Selling PressureLast Point Resistance - po-news-eg.net
GT Biopharma (GTBP) Revenue BreakdownMain Composition - Moomoo
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs - Newswire Canada
GTBP News | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
GT Biopharma (GTBP) plans reverse stock split and larger 2022 incentive plan - Stock Titan
Enterprise value to EBITDA forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - PR Newswire Canada
Enterprise value to EBITDA forward of GT Biopharma Inc – MUN:OXIA - TradingView
Enterprise value to revenue forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
Price to book forward of GT Biopharma Inc – FWB:OXIA - TradingView
Enterprise value to EBITDA forward of GT Biopharma Inc – FWB:OXIA - TradingView
Enterprise value to revenue forward of GT Biopharma Inc – FWB:OXIA - TradingView
Enterprise value to EBIT forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
Price to sales forward of GT Biopharma Inc – FWB:OXIA - TradingView
Price to earnings forward of GT Biopharma Inc – FWB:OXIA - TradingView
GT Biopharma Inc Actuals & Estimates (SWB:OXIA) - TradingView
GTBP Q1 2026 Earnings: EPS Misses Estimates as Pre‑Revenue Biotech Continues Clinical DevelopmentEPS Guidance Update - dars.gov.et
OXIA Forecast — Price Target — Prediction for 2027 - TradingView
GT Biopharma Inc Actuals & Estimates (NASDAQ:GTBP) - TradingView
GTBP Forecast — Price Target — Prediction for 2027 - TradingView
Finanzdaten der Gt Biopharma Inc-Aktie (GTBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):